National Cancer Institute, Research Contracts Branch, TCS, 6120 Executive Blvd, Room 603, MSC 7220, Bethesda Md 20892-7220

A -- MODEL DEVELOPMENT AND IN VIVO TESTING IN RODENTS SOL NCI-CM-87034-28 DUE 112697 POC Carolyn E. Barker, Contract Specialist, 301/496-8620 or Therese M. Dick, Contracting Officer, 301/496-8620 E-MAIL: Carolyn E. Barker, barkerc@rcb.nci.nih.gov. THIS IS A SOURCES SOUGHT SYNOPSIS. BASED ON THE RESPONSES RECEIVED, THIS ACQUISITION MAY BE SOLICITED AS A 100% SMALL BUSINESS SET-ASIDE, SIC CODE 8731, WITH A SIZE STANDARD OF 500 EMPLOYEES. THIS IS NOT AN RFP AND DOES NOT COMMIT THE NCI TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO RFP IS AVAILABLE AT THIS TIME. The Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) is seeking Small Business Sources with SIC Code 8731 who have the necessary experience, scientific and technical personnel, and facilities to evaluate the activity of potential anti-neoplastic compounds against in vitro cell lines, in the hollow fiber assay, and in vivo tumor systems. Maintenance of the integrity and reliability of the in vivo tumor systems is necessarily dependent upon rigorous quality control of the tumors and host animals. Further, kinetic data obtained during tumor analyses are used to assist in drug treatment scheduling and interpretation of drug testing results. This project is required so that variations in laboratory data can be identified and analyzed as to cause, e.g., animal source, tumor source, or laboratory technique. In addition, in vivo testing protocols must be established for candidate tumor models from the human tumor cell disease-oriented screening panel to provide the necessary follow-up of active materials identified for development as candidates for possible clinical trial. The Contractor will be required to perform the following specific tasks: test both standard agents and new agents identified in the in vitro and hollow fiber prescreens in in vivo protocols developed for DTP; conduct tumor cell kinetic studies including determination of doubling times and labeling indices for all tumor lines available for use in the in vivo testing program; develop working protocols suitable for drug testing using tumor models designated by the Project Officer; evaluate the response of host animals from all animal supply sources to appropriate tumor lines; evaluate the drug response and growth characteristics of tumors routinely used in the Program; evaluate the efficacy of current and new SOP's for maintaining pathogen-free tumor lines and/or animals prior to their use in the Program; prepare and maintain in vitro tumor cell cultures in support of the in vivo program; and develop new or modify existing protocols with the goal of establishing additional models (disseminated/orthotopic) for use in in vivo screening of anticancer durg candidates. The Government will designate and supply the agents to be tested. The Contractor will be expected to provide all equipment, solvents, reagents and animal facilities needed to conduct this type of work. An original and five (5) copies of your capability statement specific to this project must be submitted on or before the closing date identified above. No collect calls will be accepted. See Note(s): 25. (0316)

Loren Data Corp. http://www.ld.com (SYN# 0005 19971114\A-0005.SOL)